Matica Biotechnology, the U.S. subsidiary of CHA Biotech, has officially launched its innovative **Matica Open Access Platform**, marking a significant step forward in **drug development and manufacturing**. Biotechnology firm Cirsium Biosciences has been announced as the platform’s inaugural customer.
This groundbreaking **Matica Open Access Platform** empowers **drug developers** with unprecedented control over their **manufacturing and development processes**. It directly challenges the limitations of traditional **contract development and manufacturing organization (CDMO)** models, which often involve proprietary platforms and restrictive long-term customer commitments.
Matica highlights that customers utilizing the platform will retain full ownership of their invaluable process data and intellectual property. They also gain direct, transparent access to crucial development information. A key advantage of the **Matica Open Access Platform** is the elimination of common cell-line milestone payments and burdensome royalty fees, offering greater financial flexibility.
The launch of this platform further strengthens and expands an existing strategic partnership between Matica and Cirsium. This collaboration initially commenced in 2025 with a focus on **adeno-associated virus (AAV) vector development and manufacturing**, a critical area in **gene therapy**.
Through this synergistic collaboration, Cirsium’s innovative plant-based **AAV production technology** will be seamlessly integrated with Matica’s robust downstream processing and advanced analytical capabilities. Both companies anticipate that this integrated approach will significantly accelerate **manufacturing scale-up** from early-stage development to full commercialization, thereby substantially reducing **production timelines for gene therapies** and enhancing efficiency.
As **AAV vectors** remain among the most widely adopted and effective delivery systems in **gene therapy**, achieving optimal **manufacturing efficiency** is a paramount challenge. **Drug developers** are constantly seeking innovative solutions to reduce costs and shorten critical development cycles, a need the **Matica Open Access Platform** aims to address.
Matica is set to proudly showcase its revolutionary **Open Access Platform** at the highly anticipated **BIO International Convention 2026**. This premier biotechnology event will take place in San Diego from June 22 to 25, offering attendees an opportunity to learn more about this transformative solution.
“The **Matica Open Access Platform** empowers companies with unparalleled flexibility to design and control their unique development pathways,” stated Paul Kim, Chief Executive of Matica Biotechnology. “We are moving beyond the limitations of traditional, closed **CDMO models**, offering a truly client-centric approach.”
jwjeon7625
